Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60318 |
Name | acute promyelocytic leukemia |
Definition | An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia acute myeloid leukemia acute promyelocytic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FLT3 D835Y | Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin | acute promyelocytic leukemia | predicted - sensitive | detail... |
FLT3 D835Y | Tretinoin | acute promyelocytic leukemia | predicted - resistant | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01409161 | Phase II | Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin | Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | Recruiting | USA | 0 |
NCT01869803 | Phase I | Gemtuzumab ozogamicin | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | Approved for marketing | USA | 0 |
NCT02339740 | Phase III | Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | Active, not recruiting | USA | NZL | CAN | AUS | 2 |
NCT02688140 | Phase III | Arsenic trioxide + Idarubicin + Tretinoin Mercaptopurine + Methotrexate + Tretinoin Cytarabine + Idarubicin + Tretinoin Mitoxantrone + Tretinoin Idarubicin + Tretinoin | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) | Completed | NLD | ITA | FRA | ESP | DEU | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT04793919 | Phase II | Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin Arsenic trioxide + Tretinoin | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | Recruiting | SWE | NLD | ITA | ISR | IRL | FRA | ESP | DNK | DEU | CZE | BEL | 1 |
NCT04996030 | Phase I | Arsenic trioxide + SY-2101 SY-2101 Arsenic trioxide | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Suspended | USA | 0 |